Centauri Therapeutics closes £24 million GBP Series A investment round

Investment from Boehringer Ingelheim Venture Fund, Evotec SE, and Novo Holdings REPAIR Impact Fund Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform Appointment of Dr Johannes Zanzinger, Karen Lackey, Dr Camilla Petrycer Hansen to the Board of Directors London, UK, 16 February 2022: […]